Cyxone AB is a clinical stage biotechnology company, which engages in the development of immunomodulation drugs for the treatment of autoimmune diseases. Its product portfolio include T20K for multiple sclerosis in a preclinical program; and Rabeximod for rheumatoid arthritis and Covid-19. The company was founded by Bert Roland Kari Junno in July 13, 2015 and is headquartered in Malmo, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company